Comparison of Cognitive Rehabilitation versus Donepezil Therapy on Memory Performance, Attention, Quality of Life, and Depression among Multiple Sclerosis Patients
Table 3
Individual post hoc analyses of MANCOVA to find group differences among cognitive rehabilitation, donepezil, placebo, and control.
CR versus Control
CR versus Donepezil
CR versus Placebo
Donepezil versus Control
Donepezil versus placebo
Placebo versus Control
MD (SE)
valueb
MD (SE)
value
MD (SE)
value
MD (SE)
value
MD (SE)
value
MD (SE)
value
Everyday memory
−28.95a (13.12)
0.031
−9.89 (12.95)
0.448
−72.95 (13.81)
<0.001
−19.06 (14.50)
0.194
−63.06 (15.37)
<0.001
43.99 (15.37)
0.006
Prospective and retrospective memory
−13.34 (2.66)
<0.001
−2.80 (2.63)
0.291
−16.37 (2.83)
<0.001
−10.54 (2.95)
0.001
−13.56 (3.08)
<0.001
3.02 (3.13)
0.337
Digit span memory
2.66 (0.62)
<0.001
2.25 (0.61)
0.001
3.08 (0.66)
<0.001
0.41 (0.69)
0.553
0.83 (0.72)
0.254
−0.42 (0.73)
0.57
Physical health
15.25 (3.70)
<0.001
4.92 (3.66)
0.185
15.68 (3.92)
<0.001
10.33 (4.10)
0.015
10.76 (4.28)
0.015
−0.43 (3.66)
0.921
Mental health
22.833
<0.001
12.223
0.012
31.483
<0.001
10.610
0.049
19.260
0.001
−8.65
0.128
Depression
−12.530 (2.68)
<0.001
−6.726 (2.63)
0.004
−18.12 (2.32)
<0.001
−5.80 (3.21)
0.026
−11.40 (2.54)
<0.001
5.59 (2.69)
0.04
MANCOVA: multivariate analysis of covariance; MD: mean difference; SE: standard error; CR: cognitive rehabilitation, based on estimated marginal means MANCOVA. b Adjustment for multiple comparisons: Bonferroni.
